Neurol. praxi. 2015;16(3):171-173

Vortioxetine - the antidepressant with multimodal activity

doc. MUDr. Ján Pečeňák, CSc.
Psychiatrická klinika LF UK a UNB, Bratislava

Depressive disorder is one of the most serious health problems and is in two-way relationship with various physical diseases. Depression could be one of the primary goals of treatment in coincidence with neurological disorders.The treatment follows the general recommendations including a substantial role of treatment with antidepressants. The new antidepressant with multimodal activity – vortioxetín – has influence by multiple ways on the serotonin system and secondary influence on different signaling systems and neuronal circuits. The positive effect on cognitive functions and safety use in elderly patients has been demonstrated. The aim of this article is to inform about the pharmacological properties and results of clinical trials with vortioxetine.

Keywords: depression, antidepressants, vortioxetine, serotonin

Published: June 26, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pečeňák J. Vortioxetine - the antidepressant with multimodal activity. Neurol. praxi. 2015;16(3):171-173.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2014; 10: 1297-1307. Go to original source... Go to PubMed...
    2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-5 (5th ed.). Arlington, American Psychiatric Publishing, 2013: 991. Go to original source...
    3. Anders M, Uhrová T, Roth J. Depresivní porucha v neurologické praxi. Praha: Galén; 2005. 280 s.
    4. Anders M, Albrecht J. Nové antidepresívum s multimodálním mechanizmem účinku - vortioxetín (Lu-AA21004). Psychiatrie 2013; 17(1): 35-42.
    5. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012; 28: 1717-1724. Go to original source... Go to PubMed...
    6. Boulenger J-P, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012; 26: 1408-1416. Go to original source... Go to PubMed...
    7. EMA. European Medicinces Agency. Brintellix. Assessment report for an initial marketing authorisation application. [Internet].; Cit z: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002717/WC500159447.pdf prístup 10.4.2015a.
    8. EMA. Brintellix. Súhrn charakteristických vlastností lieku. www.ema.europe.eu; prístup 11.4.2015b
    9. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJL. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. Hay PJ, editor. PLoS Med. 2013; 10(11): e1001547. Go to original source... Go to PubMed...
    10. Jarema M, Dudek D, Czernikiewicz A. Cognitive dysfunctions in depression - underestimated symptom or new dimension? Psychiatr Pol. 2014; 48: 1105-1116. Go to original source... Go to PubMed...
    11. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012; 27: 215-223. Go to original source... Go to PubMed...
    12. Kořínková V, Novotný V, Vavrušová L. Racionálna liečba depresie. 49 Metodický list racionálnej farmakoterapie 49. 2011; 14 (1-2). Go to original source...
    13. Lam RW, Kennedy SH, McIntyre RS, Khullar A. Cognitive Dysfunction in Major Depressive Disorder: Effects on Psychosocial Functioning and Implications for Treatment. Can J Psychiatry 2014; 59: 649-654. Go to original source... Go to PubMed...
    14. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacol 2015; doi: 10.1038/npp.2015.52. [Epub ahead of print]. Go to original source... Go to PubMed...
    15. MKCH - 10. Medzinárodná štatistická klasifikácia chorôb a príbuzných zdravotných problémov. 10. revízia. Obzor; 1993: 171.
    16. Mohr P, Anders M, Masopust J. Vortioxetin v léčbě depresivní poruchy a možnosti zlepšení kognitivních funkcí. Psychiatrie 2014; 18(4): 206-211.
    17. Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014; 29: 470-482. Go to original source...
    18. Mravec B. Nervový systém: patofyziológia. Bratislava: SAP; 2013: 132.
    19. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr. 2014; 19: 121-133. Go to original source... Go to PubMed...
    20. Riedel M, Möller H-J, Obermeier M, Schennach-Wolff R, Bauer M, Adli M, et al. Response and remission criteria in major depression - a validation of current practice. J Psychiatr Res. 2010; 44: 1063-1068. Go to original source... Go to PubMed...
    21. Roiser JP, Sahakian BJ. Hot and cold cognition in depression. CNS Spectr. 2013; 18: 139-149. Go to original source... Go to PubMed...
    22. Rush AJ. STAR*D: what have we learned? Am J Psychiatry. 2007; 164: 201-204. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.